Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

NovaBay Pharma, Virbac Animal Health Ink Option Deal For Aganocide Compounds

NovaBay Pharmaceuticals Inc. (NBY: Quote) said it has reached a feasibility and option agreement with Virbac Animal Health for the development and potential commercialization of Aganocides for a number of veterinary use. As per the deal, NovaBay would receive an upfront payment plus additional support for research and development.

Virbac would conduct veterinary studies using NovaBay's Aganocide compounds in order to assess feasibility for treating several veterinary indications, and it would have the option to license exclusive worldwide rights to market Aganocides for one or more of these indications. If exercised, NovaBay may receive additional payments, including an exercise fee as well as development and pre-commercial milestones for a line of veterinary products. Also, NovaBay would receive royalties on sales of any commercialized Aganocide products to arise from this agreement.

NovaBay is developing its first-in-class, non-antibiotic, anti-infective Aganocide compounds for the topical treatment and prevention of a wide variety of bacterial, viral and fungal infections.

Click here to receive FREE breaking news email alerts for NovaBay Pharmaceuticals Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
U.S. stocks edged higher on Tuesday, with the S&P 500 posting its first-ever finish above the 2,000 mark as strong economic data and a flurry of merger news contributed to buying interest. Led by energy stocks, the S&P 500 rose 2.1 points, or 0.1%, to 2,000.02 after touching an intraday record just... South Africa's leading index rose for the second straight month in June, figures from the South African Reserve Bank showed Tuesday. The composite leading index, which measures perception on future economic conditions, rose by 0.5 percent to 100.1 in June from 99.6 in the previous month. Out of ten... German business sentiment weakened for the fourth consecutive month to the lowest level in a year in August, as the escalating crisis in Ukraine and the resultant sanctions against Russia pose downside risks to the economic activity. The Ifo business climate index fell to 106.3 in August, the lowest since July 2013, from 108 a month ago, a monthly survey conducted by the Ifo institute showed.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.